A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2002
11/14/2002	WO2002089842A1 Combination therapy using anti-egfr antibodies and anti-hormonal agents
11/14/2002	WO2002089832A2 Pharmaceutical compositions for preventing or treating th1 and th2 cell related diseases by modulating the th1/th2 ratio.
11/14/2002	WO2002089824A1 Combination of a gelatinase inhibitor and an anti-tumor agent, and uses thereof
11/14/2002	WO2002089808A1 Novel use of 2-phenyl-substituted imidazotriazinones
11/14/2002	WO2002089807A1 Timing and duration of administration of adenosine a1/a2 agonist for cardioprotection
11/14/2002	WO2002089805A2 Use of regularly scheduled high dose intravenous methotrexate therapy
11/14/2002	WO2002089804A1 Alpha-2-adrenergic agonist/fatty acid compositions
11/14/2002	WO2002089798A2 Method and compositions for treating migraines
11/14/2002	WO2002089796A2 Methods for selective immunomodulation using pimecrolimus
11/14/2002	WO2002089794A1 Method for treating neuropathic pain and pharmaceutical preparation therefor
11/14/2002	WO2002089791A2 Acne treatment with lipooxigenase inhibitors
11/14/2002	WO2002089789A1 Trimethyl lock based tetrapartate prodrugs
11/14/2002	WO2002089787A1 Potentiation of therapeutic effects of fatty acids
11/14/2002	WO2002089781A2 Methods of treating hyperlipidemia
11/14/2002	WO2002089780A2 Antiviral compounds
11/14/2002	WO2002089775A1 Coated granules based on angiotensin-converting enzyme inhibitor
11/14/2002	WO2002089770A2 Topical lamellar double membrane structure composition containing n-acyl-ethanolamine and/or a quaternary ammonium salt and/or adenosylmethionine
11/14/2002	WO2002089757A2 Use of isoflavones in cosmetic or dermatological preparations
11/14/2002	WO2002089747A2 Compositions and methods for the therapy and diagnosis of prostate cancer
11/14/2002	WO2002089743A2 Use of compositions for treating rosacea
11/14/2002	WO2002089741A2 Compositions and methods for enhancing drug delivery
11/14/2002	WO2002089736A2 Adenosine a1 receptor antagonists for treating hypoxia-induced learning and memory impairment
11/14/2002	WO2002089730A2 Compounds and methods for the modulation of cd154
11/14/2002	WO2002089584A1 Ectoparasiticidal compositions and methods of their use
11/14/2002	WO2002067831B1 Composition for freshening nostrils and sinus cavities
11/14/2002	WO2002067764A3 Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation
11/14/2002	WO2002066028A3 Pharmaceutical compositions containing fluorinated or perfluorinated carboxylic acids
11/14/2002	WO2002064550A8 Glucocorticoid receptor modulators
11/14/2002	WO2002062324A3 A treatment of oesophageal motility disorders and gastro-oesophageal reflux disease
11/14/2002	WO2002060339A3 Ophthalmic compositions for treating ocular hypertension
11/14/2002	WO2002057239A3 Pyrimidine phosphorylase as a target for imaging and therapy
11/14/2002	WO2002055152A8 Composition for inducing islet neogenesis, containing gastrin/cck receptor ligands and egf receptor ligands
11/14/2002	WO2002049634A3 Dissociated glucocorticoid receptor antagonists for the treatment of clucocorticoid associated side-effect
11/14/2002	WO2002038534A3 Substituted alkyldiamines as inhibitors of plasmepsin or related proteases
11/14/2002	WO2002034073A3 Compositions containing flavonoids and phlorizin or phloretin
11/14/2002	WO2002028906A3 Regulation of human sphingosine kinase-like protein
11/14/2002	WO2002024650B1 Pyridinone and pyridinethione derivatives having hiv inhibiting properties
11/14/2002	WO2002007713A3 Medicaments containing cilansetron for treating non-obstipated male ibs patients
11/14/2002	WO2001062235A3 A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
11/14/2002	WO2001007030A3 Compositions an inhibitor of an accrab-like efflux pump for reducung microbial resistance to drugs
11/14/2002	US20020169439 Modular infusion device and method
11/14/2002	US20020169328 Mitomycin C and pyrrolo(1,2-a)benzimidazole; exposing microorganisms to first agent which induces expression of protein which inactivates mitomycin c then to second agent which is activated by same protein which inactivates first
11/14/2002	US20020169301 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of cell proliferative disorders
11/14/2002	US20020169287 Nucleotide sequences coding polypeptide for use in the treatment of eating, dieteticad energy disorders
11/14/2002	US20020169209 Potentiation of therapeutic effects of fatty acids
11/14/2002	US20020169196 Cyclic AMP-specific phosphodiesterase inhibitors
11/14/2002	US20020169195 Combination and method of treatment of cancer utilizing a COX-2 inhibitor and an HMG-CoA inhibitor and cystine to enhance glutathione
11/14/2002	US20020169192 Peroxisome proliferator activator receptor (PPAR); amino-ethyl- phenyl derivatives
11/14/2002	US20020169183 Acridines as stimulators for Fas-mediated apoptosis
11/14/2002	US20020169181 Arylglycinamide derivatives
11/14/2002	US20020169177 Imidazole and benzimidazole caspase inhibitors and uses thereof
11/14/2002	US20020169176 Method for inhibiting retinoid skin damage
11/14/2002	US20020169174 Xanthine phosphodiesterase V inhibitors
11/14/2002	US20020169169 5-aminoalkyl and 5-aminocarbonyl substituted indole derivative useful for treatment of psychosis in a mammal
11/14/2002	US20020169166 Benzimidazoles that are useful in treating sexual dysfunction
11/14/2002	US20020169165 Substituted bicyclic derivatives for the treatment of abnormal cell growth
11/14/2002	US20020169154 Novel methods and compositions involving trk tyrosine kinase inhibitors and antineoplastic agents
11/14/2002	US20020169152 Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
11/14/2002	US20020169150 Hormone replacement therapy
11/14/2002	US20020169144 Angiogenesis inhibition
11/14/2002	US20020169140 Minimising dosage required of chemotherapeutic agents for their use in antiviral, antibacterial, antiparasitic and anticancer chemotherapy; for treating neoplasms and tumours, viral, bacterial, or parasite infections
11/14/2002	US20020169135 Administration of a G1 and/or S phase drug, which is preferably beta-lapachone, or a derivative or analog thereof, combined with a G2/M phase drug such as a taxane derivative, which is advantageously paclitaxel
11/14/2002	US20020169134 Use of substituted azetidinone compounds for the treatment of sitosterolemia
11/14/2002	US20020169128 Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
11/14/2002	US20020169109 Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
11/14/2002	US20020169103 Novel treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
11/14/2002	US20020169101 Administering a bombesin receptor antagonist
11/14/2002	US20020168782 Apparatus for use inthe detection of allergen preferential immunoglobulin in sample
11/14/2002	US20020168768 Composition for use in the generation and culturing of skin
11/14/2002	US20020168754 Nucleotide sequences coding polypeptides for use in the treatment of gastric, testicular, retinal, nervous system and immunological disorders
11/14/2002	US20020168740 Kinase for use in the treatment of inflammation, viral infection, cancer, sepsis, psoriasis and restenosis
11/14/2002	US20020168710 Anticancer agents; cardiovascular disorders; anticholesterol agents
11/14/2002	US20020168690 Peptide for use in the treatment of arthritis
11/14/2002	US20020168650 Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
11/14/2002	US20020168427 Plant extract
11/14/2002	US20020168415 Biocompatible; culture product; anticancer agents
11/14/2002	US20020168414 Rapid dehydration of proteins
11/14/2002	US20020168406 Gel overcoated with polylysine
11/14/2002	US20020168389 Oil in water emulsion; skin disorders
11/14/2002	US20020168384 Vaccine for poultry respiratory disorders
11/14/2002	US20020168366 Administering a binding agent capable of binding platelets binding platelets to the binding agent to form captured platelets, inducing activation of the captured platelets and forming a thrombus, which provides therapeutic benefit
11/14/2002	US20020168360 Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphanubeta3 antagonists in combination with other prophylactic or therapeutic agents
11/14/2002	US20020168358 Modulating the binding of the particular chemokines SLC (secondary lymphoid chemokine), and MIP-3b (macrophage inflammatory protein-3b), to immune system T-cells and dendritic cells to treat adverse inflammatory responses etc
11/14/2002	US20020168351 Fusion cells and cytokine compositions for treatment of disease
11/14/2002	US20020168350 Methods for treating disorders of neuronal deficiency with bone marrow-derived cells
11/14/2002	US20020168348 Prolonging the acceptance of a graft by administering a short course of an immunosuppressant
11/14/2002	US20020168344 Sensitization of chemotherapeutic agent resistant neoplastic cells with a virus
11/14/2002	US20020168325 Administering inhibitor of nitric oxide synthase
11/14/2002	DE10213304A1 Topical pharmaceutical composition having carrier system forming lamellar double membrane structure with water, providing good skin barrier permeation and high bioavailability without side-effects
11/14/2002	DE10122894A1 New pyrazolo(3,4-b)pyridin-3-yl)-5-pyrimidinyl sulfonates, are soluble guanyl cyclase stimulants useful e.g. for treating cardiovascular, thromboembolic or central nervous system diseases
11/14/2002	DE10122342A1 Verwendung von Isoflavonen in kosmetischen oder dermatologischen Zubereitungen Use of isoflavones in cosmetic or dermatological preparations
11/14/2002	DE10119680A1 Verwendung von Radikalfänger-Verbindungen zur Behandlung und Verhinderung von no-abhängigen Störungen der Mikrozirkulation Use of scavenger compounds for the treatment and prevention of no-dependent disorders of microcirculation
11/14/2002	CA2449166A1 Combination therapy using anti-egfr antibodies and anti-hormonal agents
11/14/2002	CA2447360A1 Pharmaceutical compositions for preventing or treating th1 and th2 cell related diseases by modulating the th1/th2 ratio.
11/14/2002	CA2446838A1 Novel mutation
11/14/2002	CA2446810A1 Epidermal growth factor receptorantisense oligonucleotides
11/14/2002	CA2446788A1 Compositions and methods for the therapy and diagnosis of prostate cancer
11/14/2002	CA2446666A1 Method for detecting progredient chronic dementia, and associated peptides and detection reagents
11/14/2002	CA2446458A1 Toll/interleukin-1 receptor adaptor protein (tirap)
11/14/2002	CA2446372A1 Ectoparasiticidal compositions and methods of their use

1 ... 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 ... 1151